PRA has significant experience in the area of respiratory/allergy clinical research. Our expertise covers a range of indications across the areas of allergic rhinitis, asthma, COPD, endocrine, cystic fibrosis and interstitial pulmonary fibrosis. PRA has been involved in the market approvals of three major drugs in this area Brovana®, Perforomist® and Fluticasone®. Our development projects have covered most respiratory/allergy drug areas including:
- Leukotriene modifier
- Inhaled and nasal corticosteroids
- Short- and long-acting beta2 agonists
- Anticholinergic agents
- Phosphodiesterase inhibitors
- Mast-cell stabilizers
- Anti-IgE antibodies
Experience and Expertise
Over the past five years, PRA has conducted nearly 100 Phase I-IV respiratory/allergy clinical trials involving over 2,500 sites and nearly 12,000 subjects. In addition, we have provided consulting services for more than 30 projects.
Key Areas of Respiratory Expertise
PRA’s respiratory therapeutic experts include:
- Board-certified pulmonologists and recognized experts in pulmonary function testing on staff
- Committee members and fellowships with major professional societies including, the American Thoracic Society, European Respiratory Society, American College of Chest Physicians and American Association for Respiratory Care
- Established relationships with investigators and leaders in respiratory clinical research
- Expertise in maximizing standardization of key respiratory assessments
Allergy Research
PRA is a leader in allergy drug research. We have had various levels of involvement with the majority the majority of approved allergy medications currently on the US market. More than 60 of our monitors and clinical team managers are experienced with allergic rhinitis studies.
